Program to Speed Foreign Drug Approvals Using U.S. Reviews
FDA has launched a Global Reliance Disclosure Program (GRDP) allowing drug and biologics manufacturers to obtain minimally redacted FDA approval packages for submission to foreign regulatory authorities, potentially accelerating access to medicines outside the U.S.
Announced 11/17, the program enables foreign regulators to rely on FDA's detailed scientific and regulatory assessments rather than duplicating portions of the agency's review. Foreign authorities retain responsibility for their own approval decisions.
The program began 10/30 with a tentative approval for lenacapavir under the President's Emergency Plan for AIDS Relief (PEPFAR), supporting HIV prevention and treatment.
Initially, GRDP is limited to PEPFAR tentative approvals, excluding abbreviated new drug applications. FDA plans to expand eligibility in 1/2027 to new molecular entity NDAs and original BLAs submitted under Section 351(a).
FDA also plans an expedited process in early 2027 for obtaining minimally redacted approval packages for previously approved drugs and licensed biologics.
Applicants must request participation within 10 calendar days of approval and confirm that the materials will support a foreign marketing application. Other requests must proceed through the Freedom of Information Act.